Evidence map›Paper›PMID 41313542›Full record

ArticleDiscover oncology2025

Causal associations between circulating metabolites and risk of neuroblastoma: a bidirectional Mendelian randomization study.

Han Wu, Zhe Zhao, Changlin Chen, Qiuhui Pan, Qizhi Diao, Chaoyan Yue

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Han Wu *Department of Clinical Laboratory, Hainan Branch, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Sanya, Hainan, China.
Zhe Zhao *Department of Orthopaedics, Xuyi People's Hospital, Huai'an, Jiangsu, China.
Changlin ChenDepartment of Otolaryngology, Xuyi People's Hospital, Huai'an, Jiangsu, China.
Qiuhui PanDepartment of Clinical Laboratory, Hainan Branch, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Sanya, Hainan, China.
Qizhi DiaoDepartment of Clinical Laboratory, Hainan Branch, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Sanya, Hainan, China. diaoqizhi@163.com.
Chaoyan YueShanghai Key Lab of Reproduction and Development, Shanghai Key Lab of Female Reproductive Endocrine Related Diseases, Obstetrics and Gynecology Hospital of Fudan University, Fangxie Road No.419, Huangpu District, Shanghai, 200011, China. 20111250007@fudan.edu.cn.

Funding

Science Foundation of Kangda College of Nanjing Medical University KD2024KYJJ217Wellcome Trust 202270
6 · The paper itself

Abstract

backgroundThe current understanding of the relationship between circulating metabolites and neuroblastoma (NB) risk is insufficient. Herein, bidirectional Mendelian randomization (MR) studies were utilized to examine the potential causal associations of metabolites and the risk of NB.

methodsSignificant single-nucleotide polymorphisms (SNPs) associated with circulating metabolites were obtained from the genome-wide association study (GWAS) in the European population (N = 7824). Summary statistics for NB were aggregated from prior GWAS studies encompassing 1,627 patients and 3,254 cancer-free children. The causality was assessed primarily by inverse-variance weighted (IVW), along with MR-Egger regression, weighted median estimator, and weighted mode method.

resultsAmong the 486 metabolites analyzed, a genetically determined elevation in blood butyrylcarnitine concentration (log

conclusionsThis research identifies bidirectional causal relationships between circulating metabolites and NB. Increased levels of blood butyrylcarnitine are associated with a reduced risk of NB, whereas lower levels of guanosine and higher levels of 3-methyl-2-oxobutyrate are indicative of NB patients. Further investigation is required for the mechanisms.

Indexed as

ButyrylcarnitineCausationCirculating metabolitesMendelian randomizationNeuroblastoma

Identifiers

PMID41313542
PMCPMC12698917

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.